Literature DB >> 15327450

Ovarian thecoma associated in the first trimester of pregnancy.

Ikuko Okada1, Shoko Nakagawa, Yuriko Takemura, Takashi Takenobu, Tatsunari Matsuoka, Hiroyuki Mandai, Tadashi Takemura.   

Abstract

Ovarian thecoma is a relatively rare tumor which occurs before and after menopause. It is extremely rare that pregnancy is complicated with thecoma. Diagnosis of ovarian tumors during pregnancy is highly problematic due to difficulties in obtaining clinical manifestations, and treatment of these tumors poses an even greater challenge. Our patient was found to have estrogen-producing thecoma accompanied by accumulation of ascites in an early phase of pregnancy. The patient underwent abdominal surgery to remove the tumor on the 13th week of gestation. This resulted in disappearance of the ascites and a favorable clinical course. Diagnosis and treatment of ovarian thecoma occurring during pregnancy are discussed with relevant references.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15327450     DOI: 10.1111/j.1447-0756.2004.00212.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  3 in total

1.  Immunohistochemical localization patterns for vimentin and other intermediate filaments in calcified ovarian fibrothecoma.

Authors:  Eric Scott Sills; Terrence B Doan; R James Mock; George R Dixson; Michael B Rohlfing
Journal:  Diagn Pathol       Date:  2006-09-11       Impact factor: 2.644

2.  Ovarian thecoma presenting with acute ovarian torsion in pregnancy; report of a rare case.

Authors:  Asieh Maleki; Maedeh Khosravi; Azaadeh Masrouri
Journal:  Clin Case Rep       Date:  2022-06-26

3.  Value of diffusion-weighted imaging combined with conventional magnetic resonance imaging in the diagnosis of thecomas/fibrothecomas and their differential diagnosis with malignant pelvic solid tumors.

Authors:  Bing Yin; Wenhua Li; Yanfen Cui; Caiting Chu; Ming Ding; Jian Chen; Ping Zhang; Xiangru Wu
Journal:  World J Surg Oncol       Date:  2016-01-08       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.